Compare FSBC & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBC | CERT |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 860.4M | 860.9M |
| IPO Year | 2021 | 2020 |
| Metric | FSBC | CERT |
|---|---|---|
| Price | $41.57 | $4.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $41.90 | $11.67 |
| AVG Volume (30 Days) | 75.3K | ★ 3.0M |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | 28.32 | ★ 87.50 |
| EPS | ★ 0.87 | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $30.25 | $4.18 |
| Revenue Next Year | $12.30 | $5.39 |
| P/E Ratio | $47.03 | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $26.26 | $4.45 |
| 52 Week High | $42.26 | $13.88 |
| Indicator | FSBC | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | 29.39 |
| Support Level | $39.93 | N/A |
| Resistance Level | $41.58 | $6.47 |
| Average True Range (ATR) | 0.95 | 0.31 |
| MACD | -0.05 | -0.14 |
| Stochastic Oscillator | 73.52 | 11.22 |
Five Star Bancorp is a bank holding company that operates in California through its subsidiary, a state-chartered non-member bank. The company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans, and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment: Banking.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.